GlassScriptPhysician profile
Zubin Yavar
NPI 1821483819
$4,405.94
in general payments reported to CMS, 2019-2025
14 companies · $697 in 2025
The $697 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $2,783 · 2022: $476 · 2023: $105 · 2024: $224 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,535.47 | 2021-2024 | Venaseal |
| Abbott Laboratories | $442.76 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $314.91 | 2021-2022 | |
| Boston Scientific Corporation | $277.08 | 2021-2025 | Rhythmia Mapping System, Latitude Communicator Power Supply |
| Siemens Medical Solutions USA, INC. | $221.06 | 2023-2025 | Biograph Vision 600 (8 Ring/64 Ct) |
| Heartflow, INC. | $152.08 | 2025 | |
| Pfizer INC. | $112.30 | 2024-2025 | |
| Inspire Medical Systems, INC. | $99.16 | 2024-2025 | Inspire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.91 | 2024-2025 | Lifevest |
| Amgen INC. | $65.25 | 2023-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $49.20 | 2024-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $24.39 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $22.06 | 2025 | |
| Novo Nordisk INC | $15.31 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zubin Yavar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.